1. Ungprasert P, Carmona EM, Utz JP ,Ryu JH,Crowson CS, Matteson EL.Epidemiology of sarcoidosis 1946-2013: a population-based study. <em>Mayo Clin Proc</em>. 2016;91(2):183-188.
2. Mahadewa TGB., Nakagawa H, Watabe T, Inoue T. Intramedullary neurosarcoidosis in the medulla oblongata: a case report. <em>Surg Neurol</em>. 2004;61:283-287.
3. Fritz D, van de Beek D, Brouwer MC. Clinical features, treatment and outcome in neurosarcoidosis: systematic review and meta-analysis. <em>BMC Neurol</em>. 2016;16(1):220.
4. Scott TF, Yandora K, Valeri A, Chie?e C, Schramke C. Aggressive therapy for neurosarcoidosis: long-term follow-up of 48 treated patients. <em>Arch Neurol</em>. 2007;64(5):691-696.
5. Carlson ML, White JR Jr., Espahbodi M, et al. Cranial base manifestations of neurosarcoidosis: a review of 305 patients. <em>Otol Neurotol</em>. 2015;36(1):156-166.
6. Gelfand JM, Bradshaw MJ, Stern BJ, et al. In?iximab for the treatment of CNS sarcoidosis: a multi-institutional series. <em>Neurology</em>. 2017;89(20):2092-2100.
7. Krumholz A, Stern BJ. Neurologic manifestations of sarcoidosis. <em>Handb Clin Neurol</em>. 2014;119:305-333
8. Nwebube CO, Bou GA, Castilho AJ, Hutto SK. Facial nerve palsy in neurosarcoidosis: clinical course, neuroinflammatory accompaniments, ancillary investigations, and response to treatment. <em>J Neurol</em>. 2022;269(10):5328-5336
9. Makimoto G, Kawakado K, Nakanishi M, etal. Heerfordt&rsquo;s syndrome associated with trigeminal nerve palsy and reversed halo sign. <em>Intern Med</em>. 2021;60(11):1747-1752
10. Bradshaw MJ, Pawate S, Koth LL, et al. Neurosarcoidosis pathophysiology, diagnosis, and treatment, <em>Neurol Neuroimmunol Neuroin?amm.</em> 2021;8:e1084.
11. Anthony J, Esper GJ, Ioachimescu A. Hypothalamic-pituitary sarcoidosis with vision loss and hypopituitarism: case series and literature review. <em>Pituitary</em>. 2016;19(1):19-29.
12. Langrand C, Bihan H, Raverot G, et al. Hypothalamo-pituitary sarcoidosis: a multicenter study of 24 patients. <em>QJM</em>. 2012;105(10):981-995.
13. Joubert B, Chapelon-Abric C, Biard L, et al. Association of prognostic factors and immunosuppressive treatment with long-term outcomes in neurosarcoidosis. <em>JAMA Neurol</em>. 2017; 74(11):1336-1344.
14. Durel CA, Marignier R, Maucort-Boulch D, et al. Clinical features and prognostic factors of spinal cord sarcoidosis: a multicenter observational study of 20 biopsyproven patients. <em>J Neurol.</em> 2016; 263(5):981-990.
15. Soni N, Bathla G, Pillenahalli Maheshwarappa R. Imaging ?ndings in spinal sarcoidosis: areport of 18 cases and review ofthe current literature. <em>Neuroradiol J</em>.2019; 32(1):17-28.
16. Flanagan EP, Kaufmann TJ, Krecke KN, et al. Discriminating long myelitis of neuromyelitis optica from sarcoidosis. <em>Ann Neurol</em>. 2016;79(3):437-447.
17. Zalewski NL,Krecke KN,Weinshenker BG,et al. Central canal enhancement and the trident sign in spinal cord sarcoidosis. <em>Neurology.</em> 2016;87(7):743-744.
18. Murphy OC, Salazar-Camelo A, Jimenez JA, et al. Clinical and MRI phenotypes of sarcoidosis-associated myelopathy. <em>Neurol Neuroimmunol Neuroin?amm</em>. 2020;7(4):e222.
19. Ramos-Casals M, P&eacute;rez-Alvarez R, Kostov B, etal. Clinical characterization and outcomes of 85 patients with neurosarcoidosis. <em>Sci Rep</em>. 2021;11(1):13735.
20. Kidd DP. Sarcoidosis of the central nervous system: clinical features, imaging, and CSF results. <em>J Neurol</em>. 2018;265(8):1906-1915
21. Jachiet V, Lhote R, Rufat P, etal. Clinical, imaging, and histological presentations and outcomes of stroke related to sarcoidosis. <em>J Neurol</em>. 2018;265(10):2333-2341.
22. Bathla G, Watal P, Gupta S, Nagpal P, Mohan S, Moritani T. Cerebrovascular manifestations of neurosarcoidosis: an underrecognized aspect of the imaging spectrum. <em>AJNR Am J Neuroradiol.</em> 2018;39(7):1194-1200.
23. Kupersmith MJ, Alban T, Zei?er B, Lefton D. Contrast-enhanced MRI in acute optic neuritis: relationship to visual performance. <em>Brain</em>. 2002;125(pt 4):812-822.
24. Tavee JO, Karwa K, Ahmed Z, Thompson N, Parambil J, Culver DA. Sarcoidosis associated small ?ber neuropathy in a large cohort: clinical aspects and response to IVIG and anti-TNF alpha treatment. <em>Respir Med</em>. 2017;126:135-138.
25. Stern BJ, Royal W III, Gelfand JM, et al. De?nition and consensus diagnostic criteria for neurosarcoidosis: from the neurosarcoidosis consortium consensus group. <em>JAMA Neurol</em>. 2018;75(12):1546-1553.
26. Cohen Aubart F, Abbara S, Maisonobe T, et al. Symptomatic muscular sarcoidosis: lessons from a nationwide multicenter study. <em>Neurol Neuroimmunol Neuroin?amm</em>. 2018;5(3):e452.
27. Ungprasert P, Carmona EM, Crowson CS, Matteson EL. Diagnostic utility of angiotensin-converting enzyme in sarcoidosis: a population-based study. <em>Lung</em>. 2016; 194(1):91-95.
28. Eurelings LEM, Miedema JR, Dalm VASH, et al. Sensitivity and specificity of serum soluble interleukin-2 receptor for diagnosing sarcoidosis in a population of patients suspected of sarcoidosis. <em>PLoS One</em>. 2019;14(10):e0223897.
29. Baud MO, Vitt JR, Robbins NM, et al. Pleocytosis is not fully responsible for low CSF glucose in meningitis. <em>Neurol Neuroimmunol Neuroinflamm</em>. 2018;5(1):e425.
30. Leonhard SE, Fritz D, Eftimov F, van der Kooi AJ, van de Beek D, Brouwer MC. Neurosarcoidosis in a tertiary referral center: a cross-sectional cohort study. <em>Medicine (Baltimore).</em> 2016;95(14):e3277.
31. Bridel C, Courvoisier DS, Vuilleumier N, Lalive PH. Cerebrospinal fluid angiotensin-converting enzyme for diagnosis of neurosarcoidosis<em>. J Neuroimmunol</em>. 2015;285:1-3.
32. Chazal T, Costopoulos M, Maillart E, et al. The cerebrospinal fluid CD4/CD8 ratio and interleukin-6 and -10 levels in neurosarcoidosis: a multicenter, pragmatic, comparative study. <em>Eur J Neurol</em>. 2019;26(10):1274-1280.
33. Zamora C, Hung SC, Tomingas C, Atkinson C, Castillo M. Engorgement of deep medullary veins in neurosarcoidosis: a common-yet-underrecognized cerebrovascular finding on SWI. <em>AJNR Am J Neuroradiol.</em> 2018;39(11):2045-2050.
34. Joseph FG, ScoldingNJ. Neurosarcoidosis: a study of 30 new cases. <em>J Neurol Neurosurg Psychiatry</em>. 2009;80(3):297-304.
35. Pawate S, Moses H, Sriram S. Presentations and outcomes of neurosarcoidosis: a study of 54 cases. <em>QJM</em>. 2009;102(7):449-460.
36. Treglia G, Annunziata S, Sobic-Saranovic D, Bertagna F, Caldarella C, Giovanella L. The role of 18F-FDG-PET and PET/CT in patients with sarcoidosis: an updated evidence-based review. <em>Acad Radiol</em>. 2014;21(5):675-684.
37. Bakkers M, Merkies IS, Lauria G, et al. Intraepidermal nerve fiber density and its application in sarcoidosis. <em>Neurology.</em> 2009;73:1142.
38. Peeples DM, Stern BJ, Jiji V, Sahni KS. Germ cell tumors masquerading as central nervous system sarcoidosis. <em>Arch Neurol.</em> 1991;48:554.
39. Stern BJ, Corbett J. Neuro-ophthalmologic manifestations of sarcoidosis. <em>Curr Treat Options Neurol.</em> 2007;9:63.
40. Agbogu BN, Stern BJ, Sewell C, Yang G. Therapeutic considerations in patients with refractory neurosarcoidosis. <em>Arch Neurol</em>. 1995;52:875.
41. Androdias G, Maillet D, Marignier R, et al. Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy. <em>Neurology</em>. 2011;76:1168.
42. Bitoun S, Bouvry D, Borie R, et al. Treatment of neurosarcoidosis: a comparative study of methotrexate and mycophenolate mofetil. <em>Neurology</em>. 2016;87:2517.
43. Pritchard C, Nadarajah K. Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients. <em>Ann Rheum Dis</em>. 2004;63:318.
44. Morcos Z. Refractory neurosarcoidosis responding to infliximab. <em>Neurology.</em> 2003;60:1220.
45. Katz JM, Bruno MK, Winterkorn JM, Nealon N. The pathogenesis and treatment of optic disc swelling in neurosarcoidosis: a unique therapeutic response to infliximab. <em>Arch Neurol</em>. 2003;60:426.
46. Pettersen JA, Zochodne DW, Bell RB, et al. Refractory neurosarcoidosis responding to infliximab. <em>Neurology</em>. 2002; 59:1660.
47. Carter JD, Valeriano J, Vasey FB, Bognar B. Refractory neurosarcoidosis: a dramatic response to infliximab. <em>Am J Med.</em> 2004;117:277.
48. Hoitsma E, Faber CG, van Santen-Hoeufft M, et al. Improvement of small fiber neuropathy in a sarcoidosis patient after treatment with infliximab. <em>Sarcoidosis Vasc Diffuse Lung Dis.</em> 2006;23:73.
49. Lord J, Paz Soldan MM, Galli J, et al. Neurosarcoidosis: Longitudinal experience in a single-center, academic healthcare system. <em>Neurol Neuroimmunol Neuroinflamm.</em> 2020;7.
50. Moravan M, Segal BM. Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil. <em>Neurology</em>. 2009;72:337.
51. Marques IB, Giovannoni G, Marta M. Mononeuritis multiplex as the first presentation of refractory sarcoidosis responsive to etanercept. <em>BMC Neurol</em>. 2014; 14:237.
52. Wijnen PA, Cremers JP, Nelemans PJ, et al. Association of the TNF-&alpha; G-308A polymorphism with TNF-inhibitor response in sarcoidosis. <em>Eur Respir J</em>. 2014; 43:1730.
53. Bomprezzi R, Pati S, Chansakul C, Vollmer T. A case of neurosarcoidosis successfully treated with rituximab. <em>Neurology</em>. 2010;75:568.
54. Sharp M, Donnelly SC, Moller DR. Tocilizumab in sarcoidosis patients failing steroid sparing therapies and anti-TNF agents. <em>Respir Med X</em>. 2019;1.
55. Damsky W, Young BD, Sloan B, et al. Treatment of multiorgan sarcoidosis with tofacitinib. <em>ACR Open Rheumatol</em>. 2020;2:106.
56. Parambil JG, Tavee JO, Zhou L, et al. Efficacy of intravenous immunoglobulin for small fiber neuropathy associated with sarcoidosis. <em>Respir Med</em>. 2011;105:101.
57. Menninger MD, Amdur RJ, Marcus RB Jr. Role of radiotherapy in the treatment of neurosarcoidosis. <em>Am J Clin Oncol.</em> 2003;26:115.